This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
Adults.
Histologically confirmed small cell lung cancer (SCLC).
At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.
Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.
Pregnancy.
Breastfeeding.
Acute psychiatric disorders.
Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).